FDA Brief

Warning letters Drugs

FDA warning letter to

Supply Center USA

High riskIssued Aug 25, 2025Posted Sep 2, 2025Center for Drug Evaluation and Research (CDER)

Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.

What happened

FDA reviewed Supply Center USA's website in May 2025 and observed that it offered Similasan eye relief products and Boiron Optique 1 Eye Irritation Relief for sale in the United States. FDA determined these ophthalmic products are unapproved new drugs and that no FDA-approved applications are in effect for them. FDA also said they are not generally recognized as safe and effective for their labeled uses.

What FDA found

  1. The products are not generally recognized as safe and effective for their labeled uses, so they are new drugs under the law.

    section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  2. No FDA-approved application is in effect for these products, so they are unapproved new drugs.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  3. Introducing or delivering these products for introduction into interstate commerce violates the FD&C Act.

    sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  4. Website claims show the products are intended to relieve or treat eye symptoms, making them drugs.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)

What FDA wants

FDA asks Supply Center USA to notify it in writing within 15 working days of the steps taken to correct the violations, including preventive steps and supporting documents. If the firm believes there is no violation, it must include its reasoning and supporting information; if corrective action cannot be completed in time, it must state why and when it will be completed.

Who should pay attention

  • retailers and online marketplaces selling Similasan or Boiron eye products
  • distributors and brands of homeopathic ophthalmic products
  • consumers using eye drops labeled homeopathic

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk